{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:58:46Z","timestamp":1783947526786,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22378329"],"award-info":[{"award-number":["22378329"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116338","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:29:56Z","timestamp":1770989396000},"page":"116338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota"],"prefix":"10.1016","volume":"174","author":[{"given":"Yifang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116338_bb0005","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"63","key":"10.1016\/j.intimp.2026.116338_bb0010","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.intimp.2026.116338_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103910","article-title":"NAFLD and NASH: etiology, targets and emerging therapies","volume":"29","author":"Wei","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2026.116338_bb0020","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.intimp.2026.116338_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116338_bb0030","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.apsb.2024.05.014","article-title":"Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2026.116338_bb0035","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.116338_bb0040","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.116338_bb0045","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gutjnl-2020-323323","article-title":"Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target","volume":"71","author":"Smati","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2026.116338_bb0050","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2026.116338_bb0055","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1248\/yakushi.22-00159-1","article-title":"The perspective of PPAR dual\/Pan agonists as therapeutic drugs against NAFLD","volume":"142","author":"Honda","year":"2022","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.intimp.2026.116338_bb0060","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/obr.12853","article-title":"The effects of oleoylethanolamide, an endogenous PPAR-alpha agonist, on risk factors for NAFLD: a systematic review","volume":"20","author":"Tutunchi","year":"2019","journal-title":"Obes. Rev."},{"key":"10.1016\/j.intimp.2026.116338_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the molecular pathways of saroglitazar: a dual PPAR alpha\/gamma agonist for managing metabolic NAFLD","volume":"155","author":"Ezhilarasan","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2026.116338_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.intimp.2026.116338_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156458","article-title":"Polysaccharides from hawthorn fruit alleviate high-fat diet-induced NAFLD in mice by improving gut microbiota dysbiosis and hepatic metabolic disorder","volume":"139","author":"Zhou","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2026.116338_bb0080","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1039\/D1FO03026D","article-title":"Ginsenoside CK ameliorates hepatic lipid accumulation via activating the LKB1\/AMPK pathway in vitro and in vivo","volume":"13","author":"Zhang","year":"2022","journal-title":"Food Funct."},{"key":"10.1016\/j.intimp.2026.116338_bb0085","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.1021\/acs.jafc.4c00245","article-title":"Ginsenoside CK alleviates DSS-induced IBD in mice by regulating tryptophan metabolism and activating aryl hydrocarbon receptor via gut microbiota modulation","volume":"72","author":"Liu","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.intimp.2026.116338_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107409","article-title":"Protective effect of ginsenoside CK against MPTP-induced Parkinson' s disease mouse model by suppressing oxidative stress and inflammation, and modulating the gut microbiota","volume":"202","author":"Yang","year":"2025","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.intimp.2026.116338_bb0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000518645","article-title":"ALT levels in treatment-naive, chronic hepatitis B patients with concurrent fatty liver disease: a US Nationwide study","volume":"40","author":"Chang","year":"2022","journal-title":"Dig. Dis."},{"key":"10.1016\/j.intimp.2026.116338_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","article-title":"Macrophage functional diversity in NAFLD - more than inflammation","volume":"18","author":"Barreby","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.intimp.2026.116338_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156724","article-title":"Inflammation-related miRNAs in obesity, CVD, and NAFLD","volume":"182","author":"Aghaei","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2026.116338_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116338_bb0115","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2026.116338_bb0120","doi-asserted-by":"crossref","unstructured":"Eslam, M., Sanyal, A. J., George, J. & International Consensus, P. (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999\u20132014 e1991.","DOI":"10.1053\/j.gastro.2019.11.312"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2026.116338_bb0125","first-page":"S24","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path!","volume":"34","author":"Katsiki","year":"2022","journal-title":"Clin. Investig. Arterioscler."},{"key":"10.1016\/j.intimp.2026.116338_bb0130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116338_bb0135","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gutjnl-2023-330826","article-title":"High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT","volume":"73","author":"Bu","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2026.116338_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jare.2023.01.008","article-title":"Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis","volume":"52","author":"Li","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.intimp.2026.116338_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149882","article-title":"Semaglutide alters gut microbiota and improves NAFLD in db\/db mice","volume":"710","author":"Mao","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116338_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115101","article-title":"Ginsenoside CK induces apoptosis in triple-negative breast cancer cells by targeting glutamine metabolism","volume":"202","author":"Zhang","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116338_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173459","article-title":"Berberine in non-alcoholic fatty liver disease-a review","volume":"14","author":"Koperska","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.intimp.2026.116338_bb0160","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1007\/s12602-024-10262-y","article-title":"Gut microbes in polycystic ovary syndrome and associated comorbidities; type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), and the potential of microbial therapeutics","volume":"16","author":"Singh","year":"2024","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"10.1016\/j.intimp.2026.116338_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24101906","article-title":"Polysaccharide from okra (Abelmoschus esculentus (L.) Moench) improves antioxidant capacity via PI3K\/AKT pathways and Nrf2 translocation in a type 2 diabetes model","volume":"24","author":"Liao","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2026.116338_bb0170","article-title":"Updates in non-alcoholic fatty liver disease (NAFLD)","volume":"50","author":"Mcneice","year":"2020","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"10.1016\/j.intimp.2026.116338_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102569","article-title":"Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress","volume":"59","author":"Abulikemu","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.intimp.2026.116338_bb0180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.bbrc.2020.04.001","article-title":"Potential use of C-phycocyanin in non-alcoholic fatty liver disease","volume":"526","author":"Ma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2026.116338_bb0185","article-title":"Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma","volume":"28","author":"Zhao","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116338_bb0190","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","article-title":"Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators","volume":"16","author":"Piccinin","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2026.116338_bb0195","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.116338_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:33:57Z","timestamp":1775306037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926001827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S1567576926001827"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116338","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ginsenoside CK regulates non-alcoholic fatty liver disease by regulating liver fat metabolism and gut microbiota","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116338"}}